HOWL — Werewolf Therapeutics Share News
0.000.00%
Last trade - 00:00Werewolf Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Werewolf Therapeutics Highlights Safety And Efficacy Data From Its Ongoing Phase 1 Clinical Trial
Brief: Werewolf Therapeutics To Present Data From Ongoing Phase 1/1B Clinical Trial Of Wtx-124 As Monotherapy And In Combination With Pembrolizumab In Solid Tumors
Brief: Werewolf Therapeutics Provides Business Update And Highlights 2024 Strategic Outlook
Brief: Adage Capital Partners Reports 8.38% Passive Stake In Werewolf Therapeutics As Of December 11- SEC Filing
Brief: Werewolf Therapeutics Q3 basic EPS USD -0.23
U.S. STOCKS ON THE MOVE-US banks, Cooper-Standard, Udemy
U.S. STOCKS ON THE MOVE-Uber, CVRx, Expedia Group
U.S. STOCKS ON THE MOVE-DigitalOcean, Werewolf Therapeutics, Gartner
Werewolf Therapeutics rises on early-stage data for lead drug
Brief: Werewolf Therapeutics Presents Preliminary Monotherapy Data From Phase 1/1b Clinical Trial
U.S. RESEARCH ROUNDUP-Apple, Cabot, Epam Systems
Brief: Werewolf Therapeutics Reports Q1 2023 Financial Results And Provides Business Update
Brief: Werewolf Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Werewolf Therapeutics - On March 16, Entered Into A First Amendment To Amended And Restated Loan And Security Agreement With Pacific Western Bank - Filing
Brief: Werewolf Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Study Of WTX-330
Brief: Werewolf Therapeutics Reports Q3 2022 Results
Brief: Werewolf Therapeutics reports Q2 results
Brief: Werewolf Therapeutics Files For Mixed Shelf Of Up To $150 Million